Robbins Geller Rudman & Dowd LLP recently announced it is investigating potential violations of U.S. federal securities laws ...
LGND READ THE FULL LGND RESEARCH REPORT In the wake of the December analyst day, Ligand Pharmaceuticals, Inc.’s (NASDAQ:LGND) ...
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc.
With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.
Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio.
Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...
Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Clinical Trials Arena on MSN
Boehringer Ingelheim’s kidney drug reduces proteinuria by 40% in Phase II trial
Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney Week ...
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...
Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results